Clinical trials: Atopy
Neonatal Jaundice, Atopic Dermatitis
Skin Care Strategies for Neonatal Jaundice Phototherapy to Prevent Atopic Dermatitis in Moderate and Severe Infants
Atopic Dermatitis (AD) is a common chronic, recurrent, and inflammatory skin disease in children. The incidence of moderate to severe AD in infants aged 1-12 months in our country is as high as 25.41%, which is related to…
- Trial name
- NCT05178433
- Testing
- Use baby moisturizers by NeoChine
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Shanghai First Maternity and Infant Hospital
Atopic Dermatitis, Emollients
Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ Balm in the Treatment of Mild to Moderate Atopic Dermatitis in Children and Adults
The therapeutic cornerstone for mild to moderate forms of atopic dermatitis (AD) relies on the combination of topical corticosteroids and emollients.
- Trial name
- AIMSI (NCT07358000)
- Testing
- Baume Relipid+
- Where
- France
- Volunteers
- 86 people
- Sponsor
- University Hospital, Caen
Atopic Dermatitis
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients.
- Trial name
- DERMIND-AD (NCT07467564)
- Testing
- Dupilumab
- Where
- 7 sites in Qatar, Saudi Arabia and 1 more
- Volunteers
- 184 people
- Sponsor
- Sanofi
Atopic Dermatitis
Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study
The purpose of this study is to evaluate the continued safety and tolerability of FB-401 in subjects 2 years of age or older with mild to moderate atopic dermatitis.
- Trial name
- NCT04936113
- Testing
- FB-401
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Forte Biosciences, Inc.
Atopic Dermatitis
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of…
- Trial name
- NCT04146363
- Testing
- Lebrikizumab
- Where
- 94 sites in United States, Australia and 8 more
- Volunteers
- 424 people
- Sponsor
- Eli Lilly and Company
Immunotherapy, Allergy and Immunology
MAPS & ITEC Cohorts: 6-8 Years Follow-up
This study represents the follow-up, age 6-8 years, of children recruited at birth into two cohorts. The first cohort, the Mite Allergen Prevention Study (MAPS) was a double-blind, randomized controlled trial of the use of house…
- Conditions
- Immunotherapy, Allergy and Immunology, Asthma
- Trial name
- NCT03763630
- Testing
- House dust-mite SLIT, Normal saline
- Where
- 2 sites in United Kingdom
- Volunteers
- 263 people
- Sponsor
- University of Southampton
Atopic Dermatitis, Food Allergy
An Innovative Probiotic Product With Antiallergic Properties
Allergic diseases are currently one of the most important problem in medicine. Research confirms that probiotics administered during the formation of the intestinal ecosystem and the maturation of the immune system can positively…
- Conditions
- Atopic Dermatitis, Food Allergy, Effects of Probiotics
- Trial name
- NCT04738565
- Testing
- Probiotic preparation, Maltodextrin
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Children's Memorial Health Institute, Poland
Atopic Dermatitis Eczema
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
This study will assess the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema).
- Trial name
- NCT04773600
- Testing
- Roflumilast Cream, Vehicle cream
- Where
- 53 sites in United States, Canada
- Volunteers
- 683 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Asthma, Allergic Sensitization
Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study
The purpose of this study is to determine whether early childhood exposure to common allergens (substances that can trigger allergies and asthma) can prevent the development of asthma in children at high risk for developing the…
- Trial name
- GPAC (NCT00346398)
- Testing
- Oral mucosal immunoprophylaxis (OMIP)
- Where
- 3 sites in United States, Australia
- Volunteers
- 51 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Eczema
Softened Water for Eczema Prevention Pilot Trial
An outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study
- Trial name
- SOFTER (NCT03270566)
- Testing
- Domestic ion-exchange water softener
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- King's College London
Atopic Dermatitis
Dupilumab in Japanese Patients With Atopic Dermatitis
Primary Objective: To evaluate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS) Secondary Objective: To evaluate the efficacy of dupilumab administered concomitantly with TCS.
- Trial name
- NCT04678882
- Testing
- Dupilumab SAR231893
- Where
- 19 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Sanofi
Atopic Dermatitis
Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 330 subjects aged 12 to 75 years old with moderate to severe atopic dermatitis.
- Trial name
- NCT04875169
- Testing
- Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Extension Treatment Active Experimental: SHR0302 Dose#1
- Where
- 52 sites in Canada, China
- Volunteers
- 336 people
- Sponsor
- Reistone Biopharma Company Limited
Dermatitis, Atopic
A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)
- Trial name
- NCT07540442
- Testing
- MG-K10 Injection (Humanized Monoclonal Antibody)
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Atopic Dermatitis
Evaluation of the Efficacy of TOPIALYSE Baume Protect+ on Atopic Dermatis
The purpose of this study is to evaluate the efficacy and tolerability of a SVR care product. As we know, atopic dermatitis is a vicious circle that must be broken, but certain aggravating factors are added to this circle.
- Trial name
- TOPIAbis (NCT06108570)
- Testing
- Cosmetic Product TOPIALYSE Baume Protect+
- Where
- 3 sites in Belgium
- Volunteers
- 60 people
- Sponsor
- SVR Group
Atopic Dermatitis
A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis
This is a multicenter, double-blind, vehicle-control study of 0.05% and 0.2% E6005 ointment. Pediatric subjects with atopic dermatitis (AD) will be grouped into two; an elder group (childhood - adolescent: 7 to 15 years of age)…
- Trial name
- NCT02094235
- Testing
- E6005 0.05%, E6005 0.2%
- Where
- 3 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Organon and Co
Cow's Milk Allergy
Epigenetic Effects Elicited By Lactobacillus GG In Children With Cow's Milk Allergy
Lactobacillus GG (LGG) is able to exert long lasting effects in children with atopic disorders. We have shown that Nutramigen LGG accelerates tolerance acquisition in infants with cow's milk allergy (CMA).
- Trial name
- NCT02062476
- Testing
- Lactobacillus GG
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Federico II University
Atopic Dermatitis (AD)
Topical Chinese Medicine and Exosome Mechanisms for Atopic Dermatitis
The goal of this clinical trial is to learn if menthol works to relieve pruritus in atopic dermatitis. The primary objectives are to evaluate the safety and clinical efficacy of menthol-containing gloves and foot-covers…
- Trial name
- NCT07693400
- Testing
- menthol-based hand and foot gloves
- Where
- Taiwan
- Volunteers
- 44 people
- Sponsor
- Taiwan Municipal An-Nan Hospital-China Medical University
Asthma in Children, Atopy
Omalizumab Before Onset of Exacerbations
OBOE is a prospective, pilot, parallel group RCT with the overall aim of examining the effect of a single dose of anti-IgE (omalizumab) vs.
- Conditions
- Asthma in Children, Atopy, Viral Upper Respiratory Infection
- Trial name
- OBOE (NCT05332067)
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Children's National Research Institute
Dermatitis, Atopic
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.
- Trial name
- NCT02118766
- Testing
- AN2728 Topical Ointment, 2%, Matching vehicle control
- Where
- United States
- Volunteers
- 763 people
- Sponsor
- Pfizer
Dermatitis, Atopic
A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
The purpose of this non-interventional study is to learn about the safety and effectivness of Cibinqo Tablet for the possible treatment of atopic dermatitis (AD). AD is a long-lasting itchy red rash, caused by a skin reaction.
- Trial name
- NCT05391061
- Testing
- Abrocitinib
- Where
- South Korea
- Volunteers
- 1,100 people
- Sponsor
- Pfizer